Phlow Partners With USP On Continuous Manufacturing
Alliance To Validate Production Processes Could Be ‘Catalyst For Industry Change’
Executive Summary
Phlow Corp has announced a strategic alliance with the US Pharmacopeia to certify and validate continuous manufacturing processes as it aims to bolster US supplies of essential medicines. The company believes the move could serve as a catalyst for wider generics industry adoption of continuous manufacturing.
You may also be interested in...
Phlow Enters Deal To Expand CDMO Services With Continuous Manufacturing
Phlow partners to provide continuous manufacturing research and development services for active pharmaceutical ingredients and registered starting materials. The company has also announced the appointment of Malcolm Berry as a senior consultant at the company’s R&D team.
FDA Seeks Feedback On Continuous Manufacturing
A draft ICH guidance on continuous manufacturing has been opened up for comment by the FDA, as continuous manufacturing becomes an increasingly prominent topic for the generics industry.
Premier Invests In Exela To Procure Shortage-Hit Generic Injectables
As hospital drug shortages continue to bite in the US, a group purchasing organization has invested in generic injectables specialist Exela Pharma Sciences to garner uninterrupted supply of 19 pharmaceutical products.